ABCL Q3 2020 Earnings — AbCellera Biologics Inc. Revenue & Financial Results | Market Cap Arena

ABCLAbCellera Biologics Inc.

$1B

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$9M+171.3% YoY

Gross Profit

$9M100.0% margin

Operating Income

-$2M-18.9% margin

Net Income

-$3M-28.8% margin

EPS (Diluted)

$-0.01

QoQ Revenue Growth

-16.6%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$8M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$142M

Total Liabilities

$53M

Stockholders' Equity

$89M

Cash & Equivalents

$91M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9M	$3M	+171.3%
Gross Profit	$9M	$668,856	+1299.7%
Operating Income	-$2M	-$715,554	-147.1%
Net Income	-$3M	$36,044	-7571.4%